NCT03856047 study context · version 1

Weight management · Phase 2

Cagrilintide: phase 2 weight management

NCT03856047 ↗

Cagrilintide · Liraglutide

What was tested?

Cagrilintide compared with placebo and liraglutide in adults with overweight or obesity, excluding diabetes. ↗

Registered primary question: Percentage change in body weight at week 26. ↗

What the reviewed report found

Journal year 2021 · Article summary reviewed 2026-09-20

Reported mean body-weight reduction ranged from 6.0% to 10.8% across cagrilintide groups and was 3.0% with placebo. Gastrointestinal events occurred more often across cagrilintide groups than with placebo.^↗

Keep in context: The trial included 706 randomized participants in total. The active groups were not masked from one another; the masking concerned active treatment versus placebo. The report distinguishes trial-product and treatment-policy analyses. ↗↗

Participants, design, limitations and sources

Registry snapshot

Registry enrollment: 706 · reported actual
Registry status: Completed
Allocation and masking: Randomized · Quadruple
Design: Parallel
Eligible ages: 18 Years; maximum not specified
Registry results: Posted in this snapshot

Registry source ↗ · Updated 2024-07-05; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.

Phase 2 weight-management trial

Design in the report: A multicenter, randomized, placebo-controlled and active-controlled dose-finding trial assessed body-weight change over 26 weeks. Participants and investigators were masked to active treatment versus placebo, but not to the different active treatments.^↗
Participants in the report: The trial randomized 706 adults without diabetes across 57 sites in ten countries, including 99 assigned to liraglutide and 101 to pooled placebo. Participants had obesity, or overweight with hypertension or dyslipidemia.^↗
Limitations: This was a sponsor-funded, 26-week Phase 2 dose-finding study in adults without diabetes, with a short off-treatment follow-up and no long-term clinical-outcomes assessment.^↗

This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →

How the study identity and sources were checked

Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.

Registry

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. ↗
Protocol identifier: NN9838-4433. Sponsor: Novo Nordisk A/S.
Retrieved 2026-09-20; SHA-256 2e186b55cc1c7724160d5c5cc0494fb1212780b5256a8046b8cf2f9ee8bcba90.

PMID 34798060

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial ↗

Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference RESULT. These source labels do not establish that every result in a paper applies to this trial.

Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 34798060. SHA-256 f2177628b98083064df17512c3dd229b760887c00cc64c4cfa4fc4e49523b12a.

Scientific summary uses the original 2026-09-20 source snapshot: SHA-256 2d3444b94dda7415d38a86129963afa54c2b4c580ba9bcf476f3411f71a61c45.